SAGE Therapeutics (SAGE) Rating Lowered to Buy at ValuEngine
SAGE has been the topic of several other reports. BidaskClub lowered SAGE Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 30th. Guggenheim initiated coverage on SAGE Therapeutics in a research note on Friday, February 22nd. They issued a “buy” rating and a $205.00 target price on the stock. Morgan Stanley lowered their target price on SAGE Therapeutics from $230.00 to $213.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 19th. Finally, Canaccord Genuity set a $220.00 target price on SAGE Therapeutics and gave the company a “buy” rating in a research note on Monday, April 8th. One analyst has rated the stock with a sell rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $201.45.
Shares of SAGE opened at $164.73 on Thursday. The firm has a market capitalization of $7.76 billion, a price-to-earnings ratio of -20.39 and a beta of 2.91. SAGE Therapeutics has a 1 year low of $79.88 and a 1 year high of $177.14.
In other news, Director Steven M. Paul sold 1,543 shares of SAGE Therapeutics stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $161.62, for a total value of $249,379.66. Following the completion of the transaction, the director now directly owns 272,777 shares in the company, valued at $44,086,218.74. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James M. Frates sold 7,500 shares of SAGE Therapeutics stock in a transaction on Wednesday, January 23rd. The shares were sold at an average price of $134.81, for a total value of $1,011,075.00. Following the completion of the transaction, the director now owns 11,735 shares of the company’s stock, valued at $1,581,995.35. The disclosure for this sale can be found here. Over the last quarter, insiders sold 175,811 shares of company stock valued at $27,771,729. 5.10% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. RTW Investments LP purchased a new position in shares of SAGE Therapeutics in the fourth quarter valued at $15,900,000. California Public Employees Retirement System grew its position in shares of SAGE Therapeutics by 3.4% in the fourth quarter. California Public Employees Retirement System now owns 62,600 shares of the biopharmaceutical company’s stock valued at $5,996,000 after purchasing an additional 2,055 shares in the last quarter. Partner Investment Management L.P. purchased a new position in shares of SAGE Therapeutics in the fourth quarter valued at $592,000. Mackenzie Financial Corp grew its position in shares of SAGE Therapeutics by 9.5% in the third quarter. Mackenzie Financial Corp now owns 17,175 shares of the biopharmaceutical company’s stock valued at $2,426,000 after purchasing an additional 1,486 shares in the last quarter. Finally, BB Biotech AG grew its position in shares of SAGE Therapeutics by 28.4% in the fourth quarter. BB Biotech AG now owns 1,375,229 shares of the biopharmaceutical company’s stock valued at $131,733,000 after purchasing an additional 303,856 shares in the last quarter.
SAGE Therapeutics Company Profile
SAGE Therapeutics, Inc operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders.
Featured Story: Float
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.